Microbicide Trials Network

MTN-013/IPM 026


A Phase I safety and drug absorption study testing 28-day use of a vaginal ring containing either dapivirine, maraviroc or the two ARVs combined that was conducted at three U.S. sites in collaboration with IPM. The study was the first clinical trial of a vaginal ring containing maraviroc, and the first to test a vaginal ring with two active drugs. Results, reported in March 2014, found the ring was safe in women and evidence of dapivirine in cervical tissue and blood. In addition, laboratory tests of tissues samples showed that dapivirine was able to block HIV infection, though levels of maraviroc were not sufficient to have a similar effect.

 

See

First Trial of Combination ARV Vaginal Ring for HIV Prevention Finds Ring Safe but One ARV Carrying the Weight

4-March-2014

  

MTN-013/IPM 026 Q&A

4-March-2014

  

First Combination ARV Vaginal Ring for HIV Prevention Being Tested in Phase I Safety Trial

15-November-2011

 

See also

MTN-013/IPM 026 Protocol